Complex dietary sphingolipids such as sphingomyelin and glycosphingolipids have been reported to inhibit development of colon cancer. This protective role may be the result of turnover to bioactive metabolites including sphingoid bases (sphingosine and sphinganine) and ceramide, which inhibit proliferation and stimulate apoptosis. The purpose of the present study was to investigate the effects of sphingoid bases and ceramides on the growth, death, and cell cycle of HT-29 and HCT-116 human colon cancer cells. The importance of the 4,5-trans double bond present in both sphingosine and C2-ceramide (a short chain analog of ceramide) was evaluated by comparing the effects of these lipids with those of sphinganine and C2-dihydroceramide (a short chain analog of dihydroceramide), which lack this structural feature. Sphingosine, sphinganine, and C2-ceramide inhibited growth and caused death of colon cancer cells in time-and concentration-dependent manners, whereas C2-dihydroceramide had no effect. These findings suggest that the 4,5-trans double bond is necessary for the inhibitory effects of C2-ceramide, but not for sphingoid bases. Evaluation of cellular morphology via fluorescence microscopy and quantitation of fragmented low-molecular weight DNA using the diphenylamine assay demonstrated that sphingoid bases and C2-ceramide cause chromatin and nuclear condensation as well as fragmentation of DNA, suggesting these lipids kill colon cancer cells by Inducing apoptosis. Flow cytometric analyses confirmed that sphingoid bases and C2-ceramide increased the number of cells in the A0 peak indicative of apoptosis and demonstrated that sphingoid bases arrest the cell cycle at G2/M phase and cause accumulation in the S phase. These findings establish that sphingoid bases and ceramide induce apoptosis In colon cancer cells and implicate them as potential mediators of the protective role of more complex dietary sphingolipids in colon carcinogenesis.
DillehayDL, WebbSK, SchmelzEM, MerrillAHJr.. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr124: 615–620, 1994.
3.
SchmelzEM, DillehayDL, WebbSK, ReiterA, AdamsJ, MerrillAHJr.. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res56: 4936–4941, 1996.
4.
SchmelzEM, BushnevAS, DillehayDL, LiottaDC, MerrillAHJr.. Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr Cancer28: 81–85, 1997.
5.
SchmelzEM, SullardsMS, DillehayDL, MerrillAHJr.. Colonic cell proliferation and aberrant crypt formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr130: 522–527, 2000.
6.
SchmelzEM, RobertsPC, KustinEM, LemonnierLA, SullardsMC, DillehayDL, MerrillAHJr.. Modulation of intracellular β-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res61: 6723–6729, 2001.
7.
DavisMA, FlawsJA, YoungM, CollinsK, ColburnNH. Effect of ceramide on intracellular glutathione determines apoptotic or necrotic cell death of JB6 tumor cells. Toxicol Sci53: 48–55, 2000.
8.
VeldmanRJ, KlappeK, HoekstraD, KokJW. Metabolism and apoptotic properties of elevated ceramide in HT-29 cells. Biochem J331: 563–569, 1998.
9.
SweeneyEA, SakakuraC, ShirahamaT, MasamuneA, OhtaH, HakomoriS-I, YasuyukiJ. Sphingosine and its methylated derivative” N,N-dimethlysphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer66: 358–366, 1996.
10.
HillMJ, MorsonBC, BusseyHJR. Aetiology of adenoma-carcinoma sequence in large bowel. Lancet1: 245–247, 1978.
11.
LiuD, el-HariryI, KarayiannakisAJ, WildingJ, ChineryR, KmiotW, McCreaPD, GullickWJ, PignatelliM. Phosphorylation of β-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest77: 557–563, 1997.
12.
RodriguesNR, RowmanA, SmithME, KerrIB, BodmerWF, GannonJV, LaneDP. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A87: 7555–7559, 1990.
13.
RedmanC, XuMJ, PengYM, ScottJA, PayneC, ClarkLC, NelsonMA. Involvement of polyamines in selenomethionine-induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis18: 1195–1202, 1997.
14.
OlivierL, CadoretA, DulucI, CapeauJ, GespachC, CherquiG, FreundJN. Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene18: 87–92, 1999.
15.
HsiLC, BaekSJ, ElingTE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res256: 563–570, 2000.
16.
IlyasM, TomlinsonIPM, RowanA, PignatelliM, BodmerWF. β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A94: 10330–10334, 1997.
17.
SchroyPC, BrownSS, KimK, JohnsonKA, MurnaneMJ, YangS, O'brienMJ, CarneyWP, KupchikHZ. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer76: 201–209, 1995.
18.
GrodenJ, JoslynG, SamowitzW, JonesD, BhattacharyyaN, SpirioL, ThliverisA, RobertsonM, EganS, MeuthM. Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res55: 1531–1539, 1995.
19.
NarayanS, JaiswalAS. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N-nitro-N-nitrosoguanidine requires p53. J Biol Chem272: 30619–30622, 1997.
20.
ZhangL, YuJ, ParkBH, KinzlerKW, VogelsteinB. Role of BAX in the apoptotic response to anticancer agents. Science290: 989–992, 2000.
21.
KutcheraW, JonesDA, MatsunamiN, GrodenJ, McIntyreTM, ZimmermanGA, WhiteRL, PrescottSM. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A93: 4816–4820, 1996.
22.
LiI-C, ChangCC, TroskoJE. Thymidylate synthetase gene as a quantitative mutation marker in Chinese hamster cells. Mutat Res243: 233–239, 1990.
MartinD, LenardoM. Microscopic quantitation of apoptotic index and cell viability using vital and fluorescent dyes. In: ColiganJE, KruisbeekAM, MarguliesD, ShevachEM, StroberW, Eds. Current Protocols in Immunology. New York: John Wiley & Sons, pp 3.17.1–3.17.39, 1994.
25.
BurtonK. Determination of DNA content with diphenylamine. Methods Enzymol12: 163–166, 1968.
26.
TelfordWG, KingLE, FrakerPJ. Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods172: 1–16, 1994.
27.
DarzynkiewiczZ, TraganosF, MelamedMR. New cell cycle compartments identified by multiparameter flow cytometry. Cytometry1: 98–108, 1980.
28.
OkazakiT, BielawskaA, BellRM, HannunYA. Role of ceramide as a lipid mediator of la, 25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem265: 15823–15831, 1990.
29.
StevensVL, NimkarS, JamisonWCL, LiottaDC, MerrillAHJr.. Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for and involvement of protein kinase C. Biochem Biophys Acta1051: 37–45, 1990.
30.
StevensVL, OwensNE, WintonEF, KinkadeJMJr., MerrillAHJr.. Modulation of retinoic acid-induced differentiation of human leukemia (HL60) cells by serum factors and sphinganine. Cancer Res50: 222–226, 1990.
31.
GoldkornT, DressierKA, MuindiJ, RadinNS, MendelsohnJ, MenaldinoD, LiottaD, KolenesnickRN. Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells: evidence that ceramide may mediate sphingosine action. J Biol Chem266: 16092–16097, 1991.
32.
EndoK, IgarashiY, NisarM, ZhouQ, HakomoriSI. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res51: 1613–1618, 1991.
33.
ObeidLM, LinardicCM, KarolakLA, HannunYA. Programmed cell death induced by ceramide. Science259: 1769–1771, 1993.
34.
SchmelzEM, Dombrink-KurtzmanMA, RobertsPC, KozutsumiY, KawasakiT, MerrillAHJr.. Induction of apoptosis by fumonisin B, in HT-29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol Appl Pharm148: 252–260, 1998.
35.
SmithER, MerrillAHJr.. Differential roles of de novo sphingolipid biosynthesis and turnover in the burst of free sphingosine and sphinganine, and their 1-phosphates and N-acyl derivatives that occurs upon changing the medium of cells in culture. J Biol Chem270: 18749–18758, 1995.
36.
SmithER, JonesPL, BossJM, MerrillAHJr.. Changing J774A.1 cells to new medium perturbs multiple signaling pathways, including the modulation of protein kinase C by endogenous sphingoid bases. J Biol Chem272: 5640–5646, 1997.
37.
WardenL-A, MenaldinoD-S, WilsonT, LiottaD-C, SmithE-R, MerrillA-H. Identification of ammonium ion and 2,6-bis(ω-aminobutyl)-3, 5-diiminopiperazine as endogenous factors that account for the “burst” of sphingosine upon changing the medium of J774 cells in culture. J Biol Chem274: 33875–33880, 1999.
38.
SchmelzEM, CrallKJ, LarocqueR, DillehayDL, MerrillAHJr.. Uptake and metabolism of sphingolipids in isolated intestinal loops. J Nutr124: 702–712, 1994.
39.
NilssonA. Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim Biophys Acta164: 575–584, 1968.
40.
NilssonA. Metabolism of cerebrosides in the intestinal tract of the rat. Biochim Biophys Acta187: 113–121, 1969.
41.
ImaizumiK, TominagaA, SatoM, SuganoM. Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr Res12: 543–548, 1992.
42.
BielawaskaA, CraneHM, LiottaDC, ObeidLM, HannunYA. Selectivity of ceramide-mediated biology: lack of activity of erythro-dihydrocermiade. J Biol Chem268: 26226–26232, 1993.
43.
TepperCL, JayadevS, LiuB, BielawskaA, WolffRA, YoneharaS, HannunYA, SeldinMF. Role for ceramide as an endogenous mediator of fas-induced cytotoxicity. Proc Natl Acad Sci U S A92: 8443–8447, 1995.
44.
SawaiH, OkazakiT, YamamotoH, OkanoH, TakedaY, TashimaM, SawadaH, OkumaM, IshikuraH, UmeharaH, DomaeN. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem270: 27326–27331, 1995.
KarasavvasN, ErukullaRK, BittmanR, LockshinR, ZakeriZ. Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. Eur J Biochem236: 729–737, 1996.
47.
XuJ, YehC-H, ChenS, HeL, SensiSL, CanzonieroLMT, ChoiDW, HsuCY. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-α/cycloheximide-induced cerebral endothelial cell death. J Biol Chem273: 16521–16526, 1998.
48.
OhtaH, SweeneyEA, MasamuneA, YatomiY, HakomoriS, IgarashiY. Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res55: 691–697, 1995.
49.
JarvisWD, FornariFA, TraylorRS, MartinHA, KramerLB, ErukullaRK, BittmanR, GrantS. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem271: 8275–8284, 1996.
50.
AhnEH, SchroederJJ. Bioactive sphingolipids are constituents of soy and dairy products. J Food Sci67: 2002.
51.
QiaoL, HanifR, SphicasE, ShiffSJ, RigasB. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol55: 53–64, 1998.
52.
PiazzaGA, RahmAK, FinnTS, FryerBH, LiH, StoumenAL, PamukcuR, AhnenDJ. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res57: 2452–2459, 1997.
53.
WaddellWR. Stimulation of apoptosis by sulindac and piroxicam. Clin Sci95: 385–388, 1998.
54.
EricksonBA, LongoWE, PanesarN, MazuskiJE, KaminskiDL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res81: 101–107, 1999.
55.
ChanTA, MorinPJ, KinzlerKW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A95: 681–686, 1998.
56.
Del BinoG, DarzynkiewiczZ. Camptothecin and teniposide, or 4'-(9-acridinylamino)-3-methane-sulfon-m-anisidide, but not mitoxantrone or doxorubucun, induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res51: 1165–1169, 1991.
57.
GorczycaW, GongJ, ArdeltB, TragancesF, DarzynkiewiczZ. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res53: 3186–3192, 1993.
58.
OkamotoS, SakaiM, UchidaJ, SaitoH. 5-Fluorouracil induces apoptotic cell death with G2 phase arrest in human breast cancer grated in nude mice. Anticancer Res16: 2699–2704, 1996.
59.
OlivierM, BautistaS, VallèsH, TheilletC. Relaxed cell cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53.Mol Carcinog23: 1–12, 1998.
60.
HuangRFS, HoYH, LinHL, WeiJS, LiuTZ. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J Nutr129: 25–31, 1999.
61.
KnowlesLM, MilnerJA. Depressed p34cdc2 kinase activity and G2/M phase arrest induced by diallyl disulfide in HCT-15 cells. Nutr Cancer30: 169–174, 1998.
62.
KnowlesLM, MilnerJA. Possible mechanism by which allyl sulfides suppress neoplastic cell proliferation. J Nutr131: 1061S–1066S, 2001.
CarethersJM, PhamTTT. Mutations of transforming growth factor-β-1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. In Vivo Attiki14: 13–20, 2000.
65.
ZhangL, YuJ, ParkBH, KinzlerKW, VogelsteinB. Role of BAX in the apoptotic response to anticancer agents. Science290: 989–992, 2000.
66.
KimJH, OhSO, JunSS, JungJS, WooJS, KimYK, LeeSH. Activation of SAPK and increase in Bak levels during ceramide and indomethacin-induced apoptosis in HT29 cells. Korean J Physiol Pharmacol3: 75–82, 1999.
